In a new impact story, the FWF highlights the work of cluster researcher Oliver Spadiut, who is the co-founder of the biotechnology company NovoArc. NovoArc has developed a lipid that makes medications more resistant to external influences. This simplifies storage and improves availability.
“Our technology makes it possible to store pharmaceuticals—including mRNA vaccines—at room temperature, eliminating the need for expensive cold chains and thus enabling medical care to be provided to patients in remote areas as well”.
Oliver Spadiut
mRNA-vaccines, which usually require expensive cold chains, can be made to withstand warmer temperatures. This significantly reduces the resources used for storing and transporting medication, which can have a crucial environmental impact.
Oliver Spadiut’s research centres on developing microbial bioprocesses for producing value-added products in red and white biotechnology. He is also working on reducing water consumption and CO2 emissions, as well as on the digitalization of these bioprocesses. His and NovoArc’s work highlights the cluster’s goal of ensuring economic growth without wasting resources.